PMCF Advises Niowave on its Non-Dilutive Financing from Novartis

PMCF Investment Banking (“PMCF”) is pleased to announce that it served as financial advisor to Niowave, Inc. (“Niowave” or the “Company”) on its non-dilutive financing from Novartis AG.

Niowave Inc., a U.S.-based global leader in medical radioisotope production, today announced a new long-term supply agreement with Novartis to deliver Actinium-225 (Ac-225). The agreement provides Novartis with a scalable supply of this critical isotope to support its growing portfolio of radioligand therapies (RLT). RLTs use a targeting component with a radioisotope to selectively target and destroy cancer cells. Financial terms of the agreement are not being disclosed.

The long-term agreement supports Novartis’s growing portfolio of RLT programs for difficult-to-treat cancers. In turn, Niowave expects to expand production capacity, and to support that growth, intends to begin construction of a new manufacturing facility in Lansing, Michigan, in early 2026.

“Our new agreement with Novartis underscores Niowave’s leading position as a trusted global supplier of medical radioisotopes,” said Mike Zamiara, Chief Executive Officer of Niowave. “Niowave’s ability to provide dependable, scalable supply of Actinium-225 will contribute to the advancement of Novartis’s targeted cancer therapies and has the potential to meaningfully transform cancer care on a global scale.”

Mike Zamiara further remarked, “PMCF’s long-term approach to transaction planning, in-depth knowledge of the healthcare industry, and excellent client service were critical as we navigated this transaction.” Bryan Hughes, Managing Director of PMCF’s Healthcare Group, added, “It has been a privilege advising Mike and the Niowave team, and are thrilled with the outcome of the transaction. We look forward to seeing the continued success of the organization”.

The transaction was announced in February 2026. PMCF and Solomon Partners served as advisors to Niowave.

About Niowave

Founded in 2005, Niowave, Inc. is a global leader in developing and operating superconducting electron linear accelerators and advancing radiochemistry procedures for medical isotope production. Headquartered in Lansing, Michigan, the company produces Ac-225 and other isotopes to support the next generation of cancer treatments, with a mission to accelerate the fight against cancer through reliable, scalable supply.